Quince Therapeutics QNCX
NASDAQ QNCX
$33.93 +1.82 (+5.67%)
At close: Aug 21, 2026 · 4:00 PM EDT

Quince Therapeutics (QNCX) Long-Term Debt Issuances (2018)

Quince Therapeutics (QNCX) posted quarterly Long-Term Debt Issuances of $250000.0 for Q1 2018.

Quince Therapeutics (QNCX) Long-Term Debt Issuances (2018) Analysis & Trends

Quince Therapeutics' Long-Term Debt Issuances history runs 1 years deep, the most recent figure standing at $250000.0 for Q1 2018.

  • In Q1 2018, Long-Term Debt Issuances changed N/A year-over-year to $250000.0; the TTM figure through Dec 2018 stood at $250000.0 (changed N/A YoY), while the FY2018 annual figure was $250000.0, changed N/A from the prior year.
  • Long-Term Debt Issuances for Q1 2018 stood at $250000.0.
  • The five-year high for Long-Term Debt Issuances was $250000.0 in Q1 2018, with the low at $250000.0 in Q1 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 Quince Therapeutics 203.43 Mn 203.43 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2018 250,000.00
Mar 31, 2018 250,000.00